Quantitation of low abundant soluble biomarkers using high sensitivity Single Molecule Counting technology
Quantitation of low abundant soluble biomarkers using high sensitivity Single Molecule Counting technology
复制标题
DOI：
10.1016/j.ymeth.2018.10.018
复制
发表时间：
2019-04-01
期刊：
影响因子：
4.8
通讯作者：
Xiao, Qiang
中科院分区：
文献类型：
--
作者：
Hwang, Joseph;Banerjee, Munmun;Xiao, Qiang
生物流体中生物标志物的定量在基础研究到患者护理管理中起着核心作用，并且在临床实验室和学术机构中常规使用。标准免疫测定，如酶联免疫吸附测定（ELISA），几十年来提供了正常和病理过程的理解。然而，近几十年来，新的免疫测定技术已经发现了血液中的许多分析物，这些分析物曾经无法使用传统的ELISA检测。为了满足定量生物流体中低丰度蛋白质的新挑战，开发了单分子计数（SM（TM））技术。这项新技术是对免疫测定程序和仪器的改进的结合。本文介绍了SMCxPR（TM）仪器、xPRO采集和分析软件以及在该仪器上验证的用于检测血清和血浆等生物体液中低丰度蛋白质的高灵敏度免疫分析试剂盒。使用这种新的技术平台，曾经无法量化的生物标志物现在可以在正常和患病的生物液体中进行量化。
Quantitation of biomarkers in biofluids plays a central role in basic research to management of patient care and is routinely used in clinical laboratories and academic institutions. Standard immunoassays, such as an enzyme-linked immunosorbent assay (ELISA), have provided understanding of both normal and pathological processes for many decades. However, in more recent decades, new immunoassay technologies have uncovered numerous analytes in blood that were once undetectable using traditional ELISAs. To meet this new challenge for quantifying low abundant proteins in biofluids, Single Molecule Counting (SM (TM)) technology was developed. This new technology is a combination of improvements to both the immunoassay procedure as well as the instrument. The aim of this article is to introduce the new SMCxPR (TM) instrument, xPRO Acquisition and Analysis software, and the high sensitivity immunoassay kits validated on this instrument for the detection of low abundant proteins in biofluids, such as serum and plasma. Using this new technology platform, biomarkers that were once unquantifiable can now be quantitated in both normal and diseased biofluids.